Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Max-Delbrück-Centrum Für Molekulare Medizin currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to 1 distinct examiner, indicating a concentrated prosecution focus at this stage. The lack of broader distribution across different examiners suggests that current strategy is tied to a specific examination path rather than a diversified filing approach across the technology area.
The prosecution activity is confined to 1 distinct art unit. Within this narrow administrative scope, MCKILLOP, JOHN CHARLES is identified as the busiest examiner. This individual is responsible for 1 busiest examiner pending action, which accounts for the entirety of the portfolio's current pending workload. Practitioners should monitor this specific examiner's patterns, as the outcome of this 1 pending office action will dictate the immediate success rate for the organization's biotechnology filings. Operating within 1 distinct art unit allows the company to develop a specialized understanding of that unit's specific examination trends.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCKILLOP, JOHN CHARLES | 1 | 61.8% | +40.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280154 | METHOD FOR GENE REPAIR IN PRIMARY HUMAN MUSCLE STEM CELLS (SATELLITE CELLS) IN VITRO AND GENETICALLY REPAIRED HUMAN MUSCLE STEM CELL | MCKILLOP, JOHN CHARLES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280154 | METHOD FOR GENE REPAIR IN PRIMARY HUMAN MUSCLE STEM CELLS (SATELLITE CELLS) IN VITRO AND GENETICALLY REPAIRED HUMAN MUSCLE STEM CELL | MCKILLOP, JOHN CHARLES | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18280154 | METHOD FOR GENE REPAIR IN PRIMARY HUMAN MUSCLE STEM CELLS (SATELLITE CELLS) IN VITRO AND GENETICALLY REPAIRED HUMAN MUSCLE STEM CELL | MCKILLOP, JOHN CHARLES | 1637 | §102§103§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial